Q-omics provides the consensus-scored CNBD2 profile across patient tissues and cancer cell-line models. CNBD2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CNBD2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, CNBD2 RNA expression shows 17,351 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where CNBD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNBD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNBD2 survival associations across molecular data types. CNBD2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNBD2 RNA expression–survival associations across cancer types. High CNBD2 expression shows unfavorable associations in UVM, LIHC, CESC and UCEC, but favorable associations in UCS and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CNBD2 RNA expression.
This table summarizes CNBD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CNBD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNBD2 shows lower tumor expression in THCA, KICH, KIRP and KIRC and higher tumor expression in LIHC and HNSC. The THCA box plot shows higher CNBD2 RNA expression in normal versus tumor tissue (log2 FC = −0.196, t-test p < 0.001).
This table shows molecular features associated with CNBD2 in patient tissues and cancer cell lines. In patient samples, CNBD2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CNBD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
